Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. L. Torres Duran, J. C. Barros Tizon, Investigators of the Spanish Group for Rexa Study (Vigo, Spain). Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study. Eur Respir J 2011; 38: Suppl. 55, 3354

Member's Comments

No comment yet.

Related content which might interest you: Alpha 1 antitrypsin (A1AT) deficiency in children with asthma in Brazil Source: Eur Respir J 2003; 22: Suppl. 45, 499s Year: 2003 Alpha 1 antitrypsin (A1AT) deficiency among patients with cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 501s Year: 2003 Patterns of exacerbations in alpha 1 antitrypsin deficiency (AATD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Intra-epithelial polymerization, accumulation and secretion of alpha1 antitrypsin (AAT) Z polymers in the lung of patients with alpha-1 antitrypsin deficiency (AATD) Source: Annual Congress 2010 - Epithelial cell biology Year: 2010 Alpha 1 - antitrypsin deficiency: diagnosis and treatment Source: Virtual Congress 2021 – Alpha 1 - antitrypsin deficiency: diagnosis and treatment Year: 2021 Alpha-1 antitrypsin deficiency in COPD patients: Time to count it in! Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Prevalence of mutations in the alpha 1 antitrypsin gene in patients with pulmonary emphysema Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019 Clinical features of alpha one antitrypsin deficiency in COPD Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Alpha 1-Antitrypsin deficiency (AATD) in patients with ARDS consequent to SARS-CoV-2 infection. Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors Year: 2021 Initial values of alpha 1 antitrypsin and transferrin in patients with pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 660s Year: 2007 Functional alterations of small airways in patients with alpha-1 antitrypsin deficiency (AATD) in a longitudinal study Source: Eur Respir J 2005; 26: Suppl. 49, 361s Year: 2005 Regional deposition of 99mTc-labelled alpha-1 antitrypsin (AAT) in patients with alpha-1 antitrypsin deficiency and cystic fibrosis (CF) compared with healthy volunteers Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007 Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD). Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases Year: 2021 Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD) Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 The results of alpha-1 antitrypsine (AAT) phenotyping in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 260s Year: 2002 Alpha-1 antitrypsin deficiency severity and the risk of COVID-19 Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19 Year: 2021 The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes Source: Eur Respir J, 56 (6) 2001441; 10.1183/13993003.01441-2020 Year: 2020 Investigating change in the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD) Source: Annual Congress 2011 - Phenotyping and monitoring of airway diseases Year: 2011 Diagnosing alpha-1 antitrypsin deficiency in Romania - first 1000 cases tested Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement? Year: 2020